SCHEMBL6500155

SCHEMBL6500155

O=C(NC1CC2CNC1C2)c1ncc(-c2cccc(Cl)c2)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 10/20 0.50
HDAC6 Q9UBN7 10/20 0.50
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
VCP P55072 1/20 0.39
FFAR1 O14842 1/20 0.38
NUDT1 P36639 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
TUBB4A P04350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500494 0.89 FAAH (0.47) HDAC1HDAC6CA12CA1CA2
SCHEMBL6490319 0.88 FAAH (0.48) HDAC1HDAC6FFAR1CA12CA1
SCHEMBL6496764 0.88 FAAH (0.48) HDAC1HDAC6CA12CA1CA2
SCHEMBL6486774 0.88 HDAC1 (0.49) HDAC1HDAC6CA12CA1CA2
SCHEMBL6500659 0.88 HDAC1 (0.46) HDAC1HDAC6NPC1RAB9AKDM4E
SCHEMBL6501701 0.88 TUBB4A (0.47) HDAC1HDAC6CA12CA1CA2
SCHEMBL6486481 0.86 HDAC1 (0.51) HDAC1HDAC6NPC1RAB9AMAPT
SCHEMBL6488148 0.85 NQO2 (0.43) HDAC1HDAC6NPC1RAB9AMAPT
SCHEMBL6488963 0.83 HDAC1 (0.53) HDAC1HDAC6NPC1RAB9AMAPT
SCHEMBL6487729 0.83 ALDH1A1 (0.57) NPC1RAB9AMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 HDAC1 467/4885HDAC6 1069/4885NPC1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.